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Abstract
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers, and it is
characterized by genetic and epigenetic alterations, as well as by inflammatory
cell infiltration among malignant and stromal cells. However, this dynamic
infiltration can be influenced by the microenvironment to promote tumor
proliferation, survival and metastasis or cancer inhibition. In particular, the
cancer microenvironment metabolites can regulate the inflammatory cells to
induce a chronic inflammatory response that can be a predisposing condition for
CRC retention. In addition, some nutritional components might contribute to a
chronic inflammatory condition by regulating various immune and inflammatory
pathways. Besides that, diet strongly modulates the gut microbiota composition,
which has a key role in maintaining gut homeostasis and is associated with the
modulation of host inflammatory and immune responses. Therefore, diet has a
fundamental role in CRC initiation, progression and prevention. In particular,
functional foods such as probiotics, prebiotics and symbiotics can have a
potentially positive effect on health beyond basic nutrition and have anti-
inflammatory effects. In this review, we discuss the influence of diet on gut
microbiota composition, focusing on its role on gut inflammation and immunity.
Finally, we describe the potential benefits of using probiotics and prebiotics to
modulate the host inflammatory response, as well as its application in CRC
prevention and treatment.
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Core tip: The host immune system plays a central role in colorectal cancer prevention
and development. However, the immune response is deeply influenced by gut microbiota
composition, which in turn is modulated by host diet. Therefore, diet could be used as a
strong ally to prevent colorectal cancer and to support its treatment.
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INTRODUCTION
Inflammation consists of an innate system with cellular and humoral responses to an
injury induced by foreign organisms, dead cells or physical irritants. The aim is to
attempt to inactivate the primary triggers and to regenerate the injured tissues. As a
response to those injuries, a multifactorial network of chemical signals initiates and
amplifies the recruitment of leukocytes (neutrophils, monocytes, and eosinophils) to
the damage sites[1]. Nevertheless, when unregulated, the inflammatory process can
become chronic with a persistent production of growth factors, reactive oxygen (RO)
and nitrogen species (NS) that interact with DNA. As result,  permanent genomic
alterations have been identified[2] that can lead to the development of diseases, such as
obesity[3], diabetes[4], and different cancers[5,6].
Inflammation  has  been  considered  a  predisposing  condition  for  tumor
development since 1863[7,8], and nowadays at least 20% of all cancers are considered to
be a direct  consequence of  a chronic inflammatory process[9].  Besides that,  many
aspects of malignancy are affected by cancer-associated inflammation[10-12]. Chronic
inflammation persistently promotes a pro-tumorigenic microenvironment, which is
rich in cytokines, the primary players regulators of crosstalk between malignant cells
and surrounding stromal cells[13].
Chronic inflammatory intestinal disorders, such as inflammatory bowel diseases
(commonly known as IBD),  including Crohn’s  disease and ulcerative colitis,  are
considered to  be  risk  factors  for  colorectal  cancer  (CRC),  as  their  initiation  and
progression  are  closely  linked  to  the  gene-environment  and  gene-gene
interactions[14-17]. In this scenario, the inflammatory microenvironment is considered a
crucial contributing factor to the development of CRC[5,10,18,19]. Even being one of the
most  studied  human  malignancies,  CRC  is  still  the  third  most  common  cancer
worldwide with 140,250 new cases estimated in 2018[20]. CRC occurs more frequently
in high-income countries[21]  mostly in sporadic forms, with only 25% of the cases
having a familial feature[22]. Furthermore, the immune system also plays an important
role in antitumor resistance[23].
Since some nutritional components, such as saturated fats, refined carbohydrates,
and red meat, may have pro-inflammatory properties, the World Cancer Research
Foundation and the American Institute for Cancer Research consider diet to be one of
the  most  important  exogenous  factors  in  CRC  etiology [ 2 4 - 2 8 ].  In  addition,
epidemiological studies have demonstrated that diet-gene interactions can cause
diverse  somatic  alterations  known  to  be  involved  in  gastrointestinal  cancer
development. These distinct alterations could be associated with the wide variation of
CRC risk and progression, among different individuals[29].  Besides that, food and
nutritional aspects have a major impact on the modulation of host gut microbiota
(GM)[30-32],  which  in  turn  have  a  crucial  symbiotic  relationship  with  the  host  by
regulating its physiology and immune system, making them important factors in
health and disease.
In this review, we point out the main aspects of the CRC immunological scenario
and the dietary impact on CRC-associated inflammation and GM modulation. Finally,
we discuss the potential  beneficial  effects  of  probiotics  and prebiotics  to  restore
intestinal  microbiota  in  CRC  prevention  and  as  a  support  to  current  anti-CRC
treatments.
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IMPACT OF DIETARY HABITS AND LIFESTYLE IN CRC
Nowadays,  it  is  estimated that 30%-40% of different cancers are caused by food,
nutrition and other lifestyle factors,  which make cancer a somewhat preventable
disease. Overwhelming epidemiological data suggest that dietary factors, particularly
those that result in overweight and obesity, influence risk, morbidity and mortality in
multiple cancers[33], especially CRC[29]. Because of this, the Department of Health and
Human Services at the National Institutes of Health and The Agency for Healthcare
Research and Quality have attempted to implement lifestyle interventions among the
population, aiming to highlight the importance of diet and healthy lifestyle for disease
prevention, including cancer[34,35].
Although diet is considered an important source for mutagenic compounds (that
may lead to tumor development)[36], distinct from other environmental factors such as
ultraviolet (commonly known as UV) rays in melanoma (of which the role is cancer is
well established), the association between diet and cancer might not be linear (Table
1).  The  link  between  nutrition  and  cancer  can  be  muddled  by  other  health-
compromising factors such as smoking and alcohol consumption, sedentary lifestyle
and exposure to environmental toxicants, all of which are well established risk factors
for cancer development[37]. Thus, even if it is hard to ‘isolate’ dietary risk factors in
epidemiological studies, animal models have irrefutably demonstrated the nutrition
influences on cancer evolution[38].  Besides that,  as demonstrated in Figure 1,  diet
components could act on cancer initiation and progression indirectly by increasing
endocrine factor production, changing inflammatory and immunological parameters,
or by changing the GM composition[37].
Direct effects of dietary components on cancer development could be represented
by the strong correlation between CRC incidence and excessive consumption of fats
and proteins (mainly of animal sources), processed meat, and substantial alcohol
consumption (more than 30 g/d)[39-41]. People are more susceptible to develop CRC
when they have an increased intake of heterocyclic amines. The main heterocyclic
amines generated are 2-amino-1-methyl-6- phenyl-imidazo[4,5-b]pyridine (PhIP), 2-
amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), and benzo[a]pyrene (Bap) a
polycyclic aromatic hydrocarbon, the first reported group of chemical carcinogens for
human cells[42]. In contrast, a vegetarian diet seems to prevent cardiovascular diseases,
type 2 diabetes and cancer[43], since fruits and vegetables contain antioxidants, which
scavenge free radicals and prevent DNA damage[44]. Vegetarian diet also includes a
variety of nutrients associated with reduced cancer risk[45].  These compounds can
protect cells by affecting the bio-transformation/detoxification pathways (phases I
and II), the cell signaling and endogenous antioxidant system[46]. Some micronutrients,
such as zinc[47]  and selenium[48],  have been extensively studied and seem to have
important  roles  in  cancer  prevention,  whereas  complex  compounds  such  as
carotenoids[49], flavonoids[50], curcumin and silymarin[51], resveratrol[52], folate[53] and
total oligomeric flavonoids[54] show both direct activity against tumor cells and in vitro
immunomodulatory effects.
In  addition,  nutrients  such  as  glucose  and  amino  acids  increase  tumor  cell
proliferation by activating growth signaling proto-oncogenes such as IGF1R, PI3K,
and AKT. In this way, deprivation of nutrients and nutrient-responsive growth factors
selectively kill high proliferative/resilient cancer cells by forcing their glycolytic asset
toward an oxidative one. In fact, calorie restriction, defined as 30%-60% less of daily
calorie requirement without malnutrition, is known to extend a healthy life span with
anticancer effects, being particularly effective in reducing the incidence, mass, and
metastasis of breast cancer (due to the profound metabolic reprogramming that builds
up adaptive stress responses)[55]. Controlled fasting has also been demonstrated to be a
promising  adjuvant  treatment  in  cancer  therapy,  mainly  when  associated  with
ketogenic diets that are low in carbohydrates and high in fats[56]. Moreover, short-term
fasting  exerts  a  beneficial  impact  on  cancer  immunosurveillance,  as  it  induces
regulatory T cell depletion, while an isocaloric diet with protein restriction has been
demonstrated to induce an IRE1α-dependent unfolded protein response in cancer
cells, increasing the number of cytotoxic CD8+ T cells (CTLs). The presence of CTLs in
the tumor environment (tumor infiltrating lymphocytes) is considered a positive
outcome of cancer treatment[55,57].
Diet can also indirectly contribute to cancer initiation and progression by favoring
obesity through over-nutrition and imbalanced diets.  Obesity is closely linked to
chronic inflammation, a significant cancer risk factor. When in a hyperplastic and
hypertrophic state, adipose tissue is overloaded with a variety of pro-inflammatory
immune cells, including classically activated macrophages, natural killer (commonly
known as NK) cells,  mast cells,  neutrophils,  dendritic cells (commonly known as
DCs), B cells, CTL and T helpers 1 (Th1) cells[58]. These cells release pro-inflammatory
factors such as interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin 1β
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Table 1  Summary of the main references that suggest that diet is harmful or protective to host
health
Pathways
Ref.
Harmful Protective
High ratio saturated fat
[27,34,39,40]
Obesity and cancer
[3,32,34,40,63]
Meat intake
[29,39,41-44,123,124] [32,45]
Alcohol intake
[41]
Carbohydrate intake
[25,28,58] [26,73]
Host microbiota and cancer
[65,87,100,133] [70,72,100,105]
Probiotic and prebiotic supplementation
[69,93-96,98,99,101,102,104,106,107,110,111,116-119]
(IL-1β),  and  interleukin  6  (IL-6),  which  lead  to  increased  local  and  systemic
inflammation  and  insulin  resistance[33],  becoming  a  strong  promoter  of  tumor
progression[59].
The  presence  of  insulin-resistant  cells  results  in  hyperinsulinemia  and
hyperglycemia, two important tumor-promoting effects; in fact, high concentrations
of insulin, glucose, and non-esterified fatty acid (NEFA) are strong promoters of cell
survival, growth, and proliferation and exert similar effects on tumor progenitors. In
addition,  high  glucose  concentrations  favor  glycolytic  cancer  cell  metabolism
characterized by enhanced glucose consumption[33]. Moreover, during obesity, adipose
tissue macrophages, which in healthy conditions are skewed towards the M2 anti-
inflammatory phenotype, are directed to pro-inflammatory M1 macrophages[60]. The
M1 macrophages produce tumor-promoting cytokines (e.g., TNF, IL-6, and IL-1b) and
chemokines, such as Monocyte chemoattractant protein-1 (MCP-1) and Macrophage
migration inhibitory factor (MIF)[61].
These  data  suggest  that  diet  modulation  could  be  used  as  a  form  of  cancer
chemoprevention in healthy individuals. In pharmacology, chemoprevention is used
to  describe  the  “use  of  pharmacological  or  natural  agents  that  inhibits  the
development of invasive cancer either by blocking the DNA damage that initiates
carcinogenesis or by arresting or reversing the progression of pre-malignant cells in
which such damage has already occurred”[62].
Diet  is  also  associated with  the  modulation  of  the  gut  microbiome that  has  a
significant role in host metabolism, nutrition and physiological features (intestinal
epithelial  cell  proliferation and differentiation,  pH, function) as well  as with the
development of the immune system and protection against pathogens[63-65]. However,
in addition to diet, the GM is influenced by numerous and incompletely elucidated
factors, such as host genetics, gender, age, anthropometric parameters, health/disease
condition, geographic and socio-economic factors, exhibiting a huge diversity among
individuals[66]. In healthy conditions, the GM plays a key role in the maintenance of
the host physiological condition by modulating the host’s immunity. The GM can
influence neutrophil migration and function[67], as well as the differentiation of T cell
subsets into Th1, Th2, and Th17 or regulatory T cells (Tregs)[68-70]. By fermenting non-
digestible complex carbohydrates such as dietary fiber, these commensal bacteria can
produce short-chain fatty acids (SCFAs), which can cross the intestinal epithelium and
reach the lamina propria, directly shaping mucosal immune responses[71].
SCFAs  modulate  the  phenotype  and  function  of  numerous  immunologically
relevant cells, such as colonic epithelial cells, macrophages, neutrophils and DCs[72].
Moreover, upon butyrate (one of the most produced SCFAs) stimulation, the CD4+
effector  T  cells  increase  T-bet  and  IFN-γ  expression,  being  able  to  exert  either
beneficial or detrimental effects on the mucosal immune system depending on its
concentration  and  immunological  milieu[73].  The  presence  of  CTLs  and  IFN-γ-
producing Th1 cells has been associated with prolonged survival[74,75], making some
SCFAs, including butyrate, propionate, and acetate, potential therapeutic tools to
modulate inflammatory responses[76,77], including for CRC treatment[78]. Nevertheless,
it is important to consider that SCFAs interact with the receptor GPR43 of colonic
Tregs, as well as act as histone deacetylase (HDAC) inhibitors in mucosal peripheral
Tregs,  which  under  healthy  conditions,  helps  to  maintain  intestinal  immune
homeostasis[79-81]. However, in the tumoral scenario (e.g., CRC), GPR43 can impair anti-
tumor immunity, decreasing effector T cell proliferation[82].
The role of the GM in CRC progression deserves special attention because there is a
strong interaction between GM, the intestinal  barrier  and immune cells[83-85].  For
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Figure 1
Figure 1  Diet components can directly or indirectly act on cancer prevention or initiation/progression.
Beneficial direct actions are exemplified by nutrients, which can directly protect cells from DNA damage and decrease
oxidative stress. A harmful direct effect is exemplified by DNA damage, activation of growth signaling proto-
oncogenes and changes in proinflammatory cytokines. Indirect beneficial and harmful effects are represented by the
modulation of gut microbiota and obesity induction, respectively. HCA: Heterocyclic amines; PAH: Polycyclic aromatic
hydrocarbon.
example,  increased  epithelial  permeability  allows  the  translocation  of  bacteria,
antigens and toxins from the lumen to the lamina propria into the blood stream, which
may initiate both local and systemic immune responses[86]. These changes can modify
inflammatory cell responses, requiring them to integrate signals (e.g., cytokines) with
cues such as local oxygen concentrations and other metabolites, promoting epithelial
cell damage that can lead to tumor development[6].
Clinical, epidemiological and experimental data have demonstrated that nutrition
and foods have a central role in cancer onset because they can change the tumor risk,
the diagnosis after the onset and the life quality after treatment, in addition to their
ability  to  ameliorate  the  adverse  effects  of  chemotherapy and radiotherapy[87,88].
“Functional foods” and “nutraceuticals” are foods or food components that supply
health  benefits  beyond basic  nutrition,  like  peptides  and proteins,  amino acids,
polyunsaturated fatty acids,  dietary fibers,  oligosaccharides,  vitamins,  minerals,
antioxidants,  probiotics  and  prebiotics,  oils  and  fatty  acids,  carbohydrates  and
fibers[89].  In  particular,  we  have  focused  on  the  immune-modulating  ability  of
probiotics and prebiotics, which make them a potential adjuvant therapy for anti-CRC
treatments.
ADJUVANT ROLE OF PROBIOTICS AND PREBIOTICS IN
CRC TREATMENTS
Probiotics are defined by the International Scientific Association for Probiotics and
Prebiotics  (commonly  known  as  ISAPP)  as  “live  microorganisms  that,  when
administered in adequate amounts, confer a health benefit on the host”[90]. They can
have health-promoting effects, such as antimicrobial activities against gut pathogens,
the ability  to  decrease blood cholesterol  levels,  reduce colitis  and inflammation,
regulate the host energy metabolism and modulate the immune system[91,92]. In the last
years, the use of probiotics and prebiotics to control the onset/progression, or their
application  as  adjuvant  therapies  in  different  diseases  such  as  influenza[93],
nonalcoholic fatty liver disease[94], pancreatitis[95], and Parkinson’s disease[96] has been
deeply investigated. In addition, their use is also being considered as a potential anti-
cancer alternative or adjuvant therapy[97], since pro/prebiotics can improve the safety
of  and decrease  the side effects  of  cancer  treatment  (as  demonstrated in  several
significant clinical trials)[98-100].
In addition to the direct role on GM modulation, probiotics present direct anti-
cancer effects by inactivating carcinogens or mutagens, altering cell differentiation
and by inducing immunomodulatory effects[101-103]. They increase immunostimulatory
activities,  improving gut barrier activity by secreting anti-carcinogenic and anti-
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oxidative molecules[104,105], and finally by activating mononuclear cells, lymphocytes
and increasing immunoglobulin A production[106,107].  Probiotic administration also
reduces the expression of certain Toll like receptors (TLRs), which increases epithelial
barrier resistance[102], and activates phagocytes, which contribute to the maintenance of
a vigilance state against tumor cells, especially in the early stages of progression[108].
The  use  of  the  Lactobacillus  rhamnosus  GG  (LGG)  strain  decreased  cellular
proliferation and carcinogenesis, due to decreased β-catenin and Bcl-2 concentrations
and increased p53 and Bax expression in rats. Moreover, this strain can reduce the
levels of pro-inflammatory molecules such as COX-2 and NF-κB-p65[103]. However, the
recent administration of a mix of Bifidobacterium spp and Lactobacillus spp (the two main
strains  studied as  probiotics  in  CRC therapies)[109]  induced the secretion of  anti-
inflammatory cytokines and up-regulation of Treg and Th2 response-related gene
expression[110].  However,  we,  in  agreement  and  supported  by  another  study,
hypothesize  that  Tregs  can  play  protective  roles  prior  to  cancer  initiation  in
“inflammation-prone” cancers, but after tumor establishment, the Tregs can be co-
opted by tumors, assuming a pro-tumorigenic role. In this way, we think that the use
of specific probiotics should be applied to prevent the early phases of CRC[111].
In  CRC,  probiotic  administration  (aiming  to  modulate  the  GM  and  immune
response) has been proven to be a promising innovative approach to counteract CRC
progression and increase chemotherapy effectiveness[112].  In an animal model, the
administration of combined Bifidobacterium longum and Bifidobacterium breve improved
cancer control, strongly reduced tumor development and increased the efficacy of a
PD-L1 blocking antibody against cancers[113]. The administration of Lactobacillus lactis
can reduce the concentration of  hydrogen peroxide (H2O2)  and catalase  activity,
decreasing tissue inflammation and colonic damage in a BALB/c mouse model. These
data suggest that bacteria are capable of affecting inflammatory mediators such as
cytokines[114]. However, the use of some bacterial strains as probiotics could have side
effects. Lactobacillus acidophilus induces CXCR4 (stromal-derived factor-1 receptor)
mRNA expression and reduces tumor growth by 50% in treated mice and induces CT-
26  cancer  cell  apoptosis,  showing  a  role  in  metastasis  prevention;  however,  its
administration also suppressed MHC-class I expression, which is crucial in cancer
surveillance[115]. Due to the heterogeneous immunomodulatory roles of probiotics, we
believe  that  a  specific  selection  of  bacterial  strain  is  fundamental  for  probiotic
effectiveness.  For  example,  disease  stage  progression  could  be  an  important
determining factor in the probiotic strain choice. Moreover, probiotic use in cancer
patients generates concern due to the risk of infection and the transfer of antibiotic
resistance. Nevertheless, randomized clinical trials have not reported a significant
increase in the risk of adverse effects following probiotic supplementation compared
to patients who received a placebo. Furthermore, probiotic supplementation has even
been proven to be safe and beneficial in these patients[116].
As an adjuvant therapy to chemo/radiotherapy in CRC patients,  some clinical
assays  have  demonstrated that  probiotics  can be  an  efficacious  treatment[117],  as
supplementation with Lactobacillus rhamnosus decreased the frequency of diarrhea,
abdominal distress and dose reduction due to intestinal toxicity compared to patients
who  received  a  placebo[118].  A  randomized  clinical  trial  about  the  efficacy  and
tolerability of Lactobacillus rhamnosus  in patients with radiation-induced diarrhea
showed  that  patients  who  received  probiotics  had  better  fecal  consistency  and
decreased bowel movements[119].
Furthermore,  since  diet  is  a  crucial  risk  factor  in  CRC susceptibility[120-122],  the
administration of prebiotics (that favor specific changes in the composition and/or
GM activity) could confer benefits upon host well-being and health[123]. Prebiotics are
carbohydrates, principally oligosaccharides, including fructooligossacharides (FOS)
xyloogliosaccharides (XOS), inulin, fructans, and galactogliosaccharides (GOS)[124,125].
They resist digestion in the human small intestine and reach the colon, where they
become substrates  to  fermentation by the  GM.  Prebiotic  administration inhibits
aberrant crypt formation and SCFA production[126], reduces cecal pH[127] and has anti-
carcinogenic  effects  on  the  presence  of  resistant  starch,  inulin  and  other  oligo-
fructans[128,129]. In addition, prebiotics have demonstrated anti-cancer properties by
downregulating the expression levels of COX-2, iNOS, NF-kB, and gastrointestinal
glutathione peroxidase by their bifidogenic effects and immunomodulatory roles.
Finally,  prebiotics  are  also  able  to  modulate  the  GM  by  inhibiting  pathogen
multiplication and enhancing cell apoptosis[130-134].
Probiotics work synergistically with prebiotics (symbiotic) to exert a beneficial
impact  on  GM  and  on  general  intestinal  health,  which  make  them  a  potential
therapeutic strategy in CRC. Lactobacillus and Bifidobacteria combined with prebiotics,
such as oligofructose and inulin, have been shown to counteract tumor progression. A
pro/prebiotic  cocktail  of  Bifidobacterium  infantum,  Lactobacillus  acidophilus,
Bifidobacterium bifidum, maltodextrin (LBB) and oligofructose increased intestinal ZO-
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1, MUC2, TLR2 and occludin expression and reduced COX-2 and TLR4 expression in
rats[102].
CONCLUSION
The  manipulation  of  nutrients  could  have  potential  implications  for  both  the
prevention  and  the  treatment  of  CRC,  since  it  can  affect  a  diverse  range  of
mechanisms, such as cell signaling, apoptosis, and immune system regulation, other
than the overlying influence on the gut microbiome.
Diet has a great ability to modulate the cellular responses to environmental stimuli,
and a balanced nutritional regime can improve immune metabolism by enhancing the
cytotoxic efficiency of CD8+ tumor infiltrating lymphocytes within the tumor mass,
showing  a  potential  role  in  improving  cancer  prognosis.  Furthermore,  diet  can
modulate the GM, and since the intestinal immune system is constantly exposed to
numerous xenobiotic  and endobiotic  metabolites (which shape mucosal  immune
function and inflammation), the intestinal microbiome and the local immune system
maintain the balance between mucosal tolerance and inflammation. In other words,
GM manipulation should be a promising treatment to improve the outcomes of CRC.
The fine mechanisms by which dietary nutrients enhance anti-cancer effects of
standard anticancer therapies have not been fully elucidated yet.
However,  the  actual  scenario  of  poor  prognosis  for  many  cancer  patients,  in
addition to the severe documented adverse events of current anti-cancer therapies
suggest the crucial need to find complementary treatments that have limited patient
toxicity and simultaneously enhance therapy responses in cancer versus normal cells.
The data discussed in this review suggest that the investigation of probiotic/prebiotic
application  as  coadjuvant  anti-cancer  treatments  will  yield  interesting  results;
however, it  is still  necessary to plan different clinical trials to confirm these very
promising results in humans.
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